Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...
Zimmer Biomet’s second quarter results were driven by strong execution in its hip franchise, robust technology sales, and progress in the U.S. sales force tr...
Zimmer Biomet (NYSE:ZBH) reported second-quarter 2026 net sales of $2.177 billion, up 4.8% on a reported basis and 4.0% on an organic constant-currency basis, as growth in hips, specialty businesses and technology helped offset weaker performance in certain other product lines.
U.S. organic constan
Medical device company Zimmer Biomet (NYSE:ZBH) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 4.8% year on year to $2...
Medical device company Zimmer Biomet (NYSE:ZBH) announced better-than-expected revenue in Q2 CY2026, with sales up 4.8% year on year to $2.18 billion. Its no...
Medical device company Zimmer Biomet (NYSE:ZBH) will be announcing earnings results this Wednesday before market hours. Here’s what to look for. Zimmer Biome...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be...
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the surgical equipment & consumables - diversified industry, incl...
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - div...
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destocking...
Over the past six months, Zimmer Biomet’s shares (currently trading at $85.45) have posted a disappointing 12.4% loss, well below the S&P 500’s 9.1% gain. Th...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
What Happened? Shares of medical device company Zimmer Biomet (NYSE:ZBH) jumped 4.9% in the afternoon session after the company announced it increased its sh...
